Buruli-Ulkus – Diagnose und Therapie der infektiösen tropischen Hauterkrankung

Das Buruli-Ulkus – verursacht durch Mycobacterium ulcerans – ist neben Tuberkulose und Lepra die wichtigste mykobakterielle Erkrankung. Die typischen Ulzera mit weit unterminierten Rändern werden vorwiegend in Westafrika gesehen, seltener in Zentral- oder Ostafrika sowie einigen tropischen Regionen in Asien, Amerika und im West-Pazifik. In der Reisemedizin hat das Buruli-Ulkus nur eine geringe Bedeutung. Es sollte aber bei Migranten aus Endemiegebieten mit unklaren Ulzerationen differenzialdiagnostisch in Betracht gezogen werden. Die Homepage der „Global Buruli Ulcer Initiative“ der WHO (www.who.int/buruli) hat aktuelle Empfehlungen zu Diagnostik und Therapie sowie epidemiologische Daten.

Buruli ulcer – caused by Mycobacterium ulcerans – is the most important mycobacterial disease besides tuberculosis and leprosy. The typical ulcers with wide undermined edges are mainly seen in West Africa, but also in Central- or East-Africa as well as in some tropical regions of Asia, America and in the West-Pacific. Although the importance of Buruli ulcer in the range of travel medicine is rather low, it should be considered as differential diagnostics for patients with unclear ulcers coming from endemical disease areas. Updated recommendations concerning diagnostics, therapy as well as epidemiologic data can be found at the homepage of the „Global Buruli Ulcer Initiative“ of the WHO (www.who.int/buruli).

Key words

Buruli ulcer - Mycobacterium ulcerans - mycobacteria - skin ulcer

Literatur

• 1 Demangel C, Stinear TP, Cole ST. Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans.  Nat Rev Microbiol. 2009;  7 50-60
• 2 Röltgen K, Qi W, Ruf Mt et al.. Single nucleotide polymorphism typing of Mycobacterium ulcerans reveals focal transmission of buruli ulcer in a highly endemic region of Ghana.  PLoS Negl Trop Dis. 2010;  4
• 3 Johnson RC, Nackers F, Glynn JR et al.. Association of HIV infection and Mycobacterium ulcerans disease in Benin.  AIDS. 2008;  22 901-3
• 4 Ezzedine K, Pistone T, Cottin J et al.. Buruli ulcer in long-term traveler to Senegal.  Emerg Infect Dis. 2009;  15 118-9
• 5 McGann H, Stragier P, Portaels F et al.. Buruli ulcer in United Kingdom tourist returning from Latin America.  Emerg Infect Dis. 2009;  15 1827-9
• 6 Vandelannoote K, Durnez L, Amissah D et al.. Application of real-time PCR in Ghana, a Buruli ulcer-endemic country, confirms the presence of Mycobacterium ulcerans in the environment.  FEMS Microbiol Lett. 2010;  304 191-4
• 7 Meyers WM, Shelly WM, Connor DH et al.. Human Mycobacterium ulcerans infections developing at sites of trauma to skin.  Am J Trop Med Hyg. 1974;  23 919-23
• 8 Johnson PD, Lavender CJ. Correlation between Buruli ulcer and vector-borne notifiable diseases, Victoria, Australia.  Emerg Infect Dis. 2009;  15 614-5
• 9 Silva MT, Portaels F, Pedrosa J. Pathogenetic mechanisms of the intracellular parasite Mycobacterium ulcerans leading to Buruli ulcer.  Lancet Infect Dis. 2009;  9 699-710
• 10 Boulkroun S, Guenin-Macé L, Thoulouze MI et al.. Mycolactone suppresses T cell responsiveness by altering both early signaling and posttranslational events.  J Immunol. 2010;  184 1436-44
• 11 Phillips RO, Sarfo FS, Osei-Sarpong F et al.. Sensitivity of PCR targeting Mycobacterium ulcerans by use of fine-needle aspirates for diagnosis of Buruli ulcer.  J Clin Microbiol. 2009;  47 924-6
• 12 Sarfo FS, Phillips RO, Rangers B et al.. Detection of Mycolactone A/B in Mycobacterium ulcerans-Infected Human Tissue.  PLoS Negl Trop Dis. 2010;  4
• 13 Sarfo FS, Phillips R, Asiedu K et al.. Clinical efficacy of combination rifampicin and streptomycin for treatment of M. ulcerans disease.  Antimicrob Agents Chemother. 2010;  54 3678-85
• 14 Nienhuis WA, Stienstra Y, Thompson WA et al.. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial.  Lancet. 2010;  375 664-72
• 15 Junghanss T, Um A Boock, Vogel M et al.. Phase change material for thermotherapy of Buruli ulcer: a prospective observational single centre proof-of-principle trial.  PLoS Negl Trop Dis. 2009;  3
• 16 Kibadi K, Boelaert M, Frage AG et al.. Response to treatment in a prospective cohort of patients with large ulcerated lesions suspected to be Buruli Ulcer (Mycobacterium ulcerans disease).  PLoS Negl Trop Dis. 2010;  4
• 17 Sopoh GE, Dossou AD, Brun LV et al.. Severe multifocal form of buruli ulcer after streptomycin and rifampin treatment: comments on possible dissemination mechanisms.  Am J Trop Med Hyg. 2010;  83 307-13
• 18 Huygen K, Adjei O, Affolabi D et al.. Buruli ulcer disease: prospects for a vaccine.  Med Microbiol Immunol. 2009;  198 69-77

Korrespondenz